Topics:
Breast Cancer • Medical Oncology • Triple negative • Neoadjuvant chemotherapy • Residual disease
What is your approach to patients with locally advanced triple negative breast cancer with residual disease at the time of surgery?
Are you using post-neoadjuvant Xeloda based on preliminary data from the CREATE-X trial? Does BRCA mutation influence your decision?
Answer from: Medical Oncologist at Academic Institution
These patients remain at very high risk for metastatic recurrence and therefore should receive adjuvant chemotherapy with capecitabine as standard of care, radiation therapy, and considered for participation in the following adjuvant clinical trials: (1) SWOG S1418 (pembrolizumab versus ob...
Sign in or Register to read more